Neurodegenerative diseases (ND) primarily affect neurons in the human brain and are currently incurable. Neurotrophins have been shown to control a number of aspects of survival, development and function of neurons and they have been proposed as therapeutic agents for neurodegenerative diseases. However, the poor pharmacokinetic properties of neurotrophins prohibit their use as drugs. EuroNeurotrophin will address the major limitations of neurotrophins by developing novel small molecule, neurotrophin mimetics with favourable profiles of stability, tissue penetration and targeted biological actions.
Neurodegenerative diseases (ND) like Alzheimer’s disease or Parkinson’s disease are on the rise in developed societies worldwide. Currently, there exists no cure for any ND and most of the available drugs fail to tackle ND pathogenesis.
Preclinical studies point to the therapeutic potential of neurotrophins, which have been shown to control a number of aspects of survival, development and function of neurons. However, the poor pharmacokinetic properties of neurotrophins render their use as drugs prohibitive.
The key idea of the project is to address this limitation by developing novel small molecule, neurotrophin mimetics with favourable profiles of stability, tissue penetration and targeted biological actions. EuroNeurotrophin will be the first European consortium to study small molecule neurotrophin mimetics in depth, use them as molecular probes to interrogate neurotrophins, and emphasise their clinical translation.
The network has been designed to address the need for the development of new ND treatments through the collaborative training of 14 early-stage researchers. It consists of 10 leading European research groups and 6 private companies of complementary expertise covering all steps of drug discovery and development. Collectively the consortium members will conduct a unique training programme that could not be achieved by doctoral training within a single academic institution and accelerate the translation of identified drug candidate molecules into the market.
accelopment is a Partner Organisation in EuroNeurotrophin. We are involved in two areas of the project – coordinating the communication and dissemination activities as well as contributing to the training activities with a Grant writing & research management course.